O	0	10	Randomized
O	11	16	phase
O	17	20	III
O	21	26	study
O	27	29	of
B-intervention	30	39	docetaxel
O	40	48	compared
O	49	53	with
B-control	54	64	paclitaxel
O	65	67	in
O	68	78	metastatic
O	79	85	breast
O	86	92	cancer
O	92	93	.

O	94	98	This
O	99	109	randomized
O	109	110	,
O	111	121	controlled
O	121	122	,
O	123	134	multicenter
O	134	135	,
O	136	140	open
O	140	141	-
O	141	146	label
O	146	147	,
O	148	153	phase
O	154	157	III
O	158	163	study
O	164	172	compared
O	173	182	docetaxel
O	183	189	versus
O	190	200	paclitaxel
O	201	203	in
B-eligibility	204	212	patients
I-eligibility	213	217	with
I-eligibility	218	226	advanced
I-eligibility	227	233	breast
I-eligibility	234	240	cancer
I-eligibility	241	245	that
I-eligibility	246	249	had
I-eligibility	250	260	progressed
I-eligibility	261	266	after
I-eligibility	267	269	an
I-eligibility	270	283	anthracycline
I-eligibility	283	284	-
I-eligibility	284	294	containing
I-eligibility	295	307	chemotherapy
I-eligibility	308	315	regimen
O	315	316	.

O	317	325	Patients
O	326	327	(
O	327	328	n
O	329	330	=
B-total-participants	331	334	449
O	334	335	)
O	336	340	were
O	341	349	randomly
O	350	358	assigned
O	359	361	to
O	362	369	receive
O	370	376	either
O	377	386	docetaxel
O	387	390	100
O	391	393	mg
O	393	394	/
O	394	396	m2
O	397	398	(
O	398	399	n
O	400	401	=
B-intervention-participants	402	405	225
O	405	406	)
O	407	409	or
O	410	420	paclitaxel
O	421	424	175
O	425	427	mg
O	427	428	/
O	428	430	m2
O	431	432	(
O	432	433	n
O	434	435	=
B-control-participants	436	439	224
O	439	440	)
O	441	443	on
O	444	447	day
O	448	449	1
O	449	450	,
O	451	456	every
O	457	459	21
O	460	464	days
O	465	470	until
O	471	476	tumor
O	477	488	progression
O	488	489	,
O	490	502	unacceptable
O	503	511	toxicity
O	511	512	,
O	513	515	or
O	516	526	withdrawal
O	527	529	of
O	530	537	consent
O	537	538	.

O	539	541	In
O	542	545	the
O	546	552	intent
O	552	553	-
O	553	555	to
O	555	556	-
O	556	561	treat
O	562	572	population
O	572	573	,
O	574	578	both
O	579	582	the
B-outcome	583	589	median
I-outcome	590	597	overall
I-outcome	598	606	survival
O	607	608	(
O	608	610	OS
O	610	611	,
B-iv-cont-median	612	614	15
I-iv-cont-median	614	615	.
I-iv-cont-median	615	616	4
O	617	618	v
B-cv-cont-median	619	621	12
I-cv-cont-median	621	622	.
I-cv-cont-median	622	623	7
I-cv-cont-median	624	630	months
O	630	631	;
O	632	638	hazard
O	639	644	ratio
O	645	646	[
O	646	648	HR
O	648	649	]
O	649	650	,
O	651	652	1
O	652	653	.
O	653	655	41
O	655	656	;
O	657	659	95
O	659	660	%
O	661	663	CI
O	663	664	,
O	665	666	1
O	666	667	.
O	667	669	15
O	670	672	to
O	673	674	1
O	674	675	.
O	675	677	73
O	677	678	;
O	679	680	P
O	681	682	=
O	683	684	.
O	684	686	03
O	686	687	)
O	688	691	and
O	692	695	the
B-outcome	696	702	median
I-outcome	703	707	time
I-outcome	708	710	to
I-outcome	711	722	progression
O	723	724	(
O	724	727	TTP
O	727	728	,
B-iv-cont-median	729	730	5
I-iv-cont-median	730	731	.
I-iv-cont-median	731	732	7
I-iv-cont-median	733	739	months
O	740	741	v
B-cv-cont-median	742	743	3
I-cv-cont-median	743	744	.
I-cv-cont-median	744	745	6
I-cv-cont-median	746	752	months
O	752	753	;
O	754	756	HR
O	756	757	,
O	758	759	1
O	759	760	.
O	760	762	64
O	762	763	;
O	764	766	95
O	766	767	%
O	768	770	CI
O	770	771	,
O	772	773	1
O	773	774	.
O	774	776	33
O	777	779	to
O	780	781	2
O	781	782	.
O	782	784	02
O	784	785	;
O	786	787	P
O	788	789	<
O	790	791	.
O	791	795	0001
O	795	796	)
O	797	800	for
O	801	810	docetaxel
O	811	815	were
O	816	829	significantly
O	830	836	longer
O	837	841	than
O	842	845	for
O	846	856	paclitaxel
O	856	857	,
O	858	861	and
O	862	865	the
B-outcome	866	873	overall
I-outcome	874	882	response
I-outcome	883	887	rate
O	888	889	(
B-outcome	889	892	ORR
O	892	893	,
B-iv-bin-percent	894	896	32
I-iv-bin-percent	896	897	%
O	898	899	v
B-cv-bin-percent	900	902	25
I-cv-bin-percent	902	903	%
O	903	904	;
O	905	906	P
O	907	908	=
O	909	910	.
O	910	912	10
O	912	913	)
O	914	917	was
O	918	924	higher
O	925	928	for
O	929	938	docetaxel
O	938	939	.

O	940	945	These
O	946	953	results
O	954	958	were
O	959	968	confirmed
O	969	971	by
O	972	984	multivariate
O	985	993	analyses
O	993	994	.

O	995	998	The
O	999	1008	incidence
O	1009	1011	of
O	1012	1021	treatment
O	1021	1022	-
O	1022	1029	related
B-outcome	1030	1041	hematologic
I-outcome	1042	1045	and
I-outcome	1046	1060	nonhematologic
I-outcome	1061	1071	toxicities
O	1072	1075	was
O	1076	1083	greater
O	1084	1087	for
O	1088	1097	docetaxel
O	1098	1102	than
O	1103	1106	for
O	1107	1117	paclitaxel
O	1117	1118	;
O	1119	1126	however
O	1126	1127	,
O	1128	1135	quality
O	1135	1136	-
O	1136	1138	of
O	1138	1139	-
O	1139	1143	life
O	1144	1150	scores
O	1151	1155	were
O	1156	1159	not
O	1160	1173	statistically
O	1174	1183	different
O	1184	1191	between
O	1192	1201	treatment
O	1202	1208	groups
O	1209	1213	over
O	1214	1218	time
O	1218	1219	.

O	1220	1229	Docetaxel
O	1230	1233	was
O	1234	1242	superior
O	1243	1245	to
O	1246	1256	paclitaxel
O	1257	1259	in
O	1260	1265	terms
O	1266	1268	of
B-outcome	1269	1271	OS
O	1272	1275	and
B-outcome	1276	1279	TTP
O	1279	1280	.

B-outcome	1281	1284	ORR
O	1285	1288	was
O	1289	1295	higher
O	1296	1299	for
O	1300	1309	docetaxel
O	1309	1310	.

B-outcome	1311	1322	Hematologic
I-outcome	1323	1326	and
I-outcome	1327	1341	nonhematologic
I-outcome	1342	1352	toxicities
O	1353	1361	occurred
O	1362	1366	more
O	1367	1377	frequently
O	1378	1380	in
O	1381	1384	the
O	1385	1394	docetaxel
O	1395	1400	group
O	1400	1401	.

O	1402	1405	The
O	1406	1412	global
O	1413	1420	quality
O	1420	1421	-
O	1421	1423	of
O	1423	1424	-
O	1424	1428	life
O	1429	1435	scores
O	1436	1440	were
O	1441	1448	similar
O	1449	1452	for
O	1453	1457	both
O	1458	1464	agents
O	1465	1469	over
O	1470	1474	time
O	1474	1475	.
